153 related articles for article (PubMed ID: 9174621)
41. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.
Conway JG; Andrews RC; Beaudet B; Bickett DM; Boncek V; Brodie TA; Clark RL; Crumrine RC; Leenitzer MA; McDougald DL; Han B; Hedeen K; Lin P; Milla M; Moss M; Pink H; Rabinowitz MH; Tippin T; Scates PW; Selph J; Stimpson SA; Warner J; Becherer JD
J Pharmacol Exp Ther; 2001 Sep; 298(3):900-8. PubMed ID: 11504783
[TBL] [Abstract][Full Text] [Related]
42. Expression and function of tumour necrosis factor-alpha-converting enzyme in the central nervous system.
Moro MA; Hurtado O; Cárdenas A; Romera C; Madrigal JL; Fernández-Tomé P; Leza JC; Lorenzo P; Lizasoain I
Neurosignals; 2003; 12(2):53-8. PubMed ID: 12876399
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
Xue CB; Voss ME; Nelson DJ; Duan JJ; Cherney RJ; Jacobson IC; He X; Roderick J; Chen L; Corbett RL; Wang L; Meyer DT; Kennedy K; DeGradodagger WF; Hardman KD; Teleha CA; Jaffee BD; Liu RQ; Copeland RA; Covington MB; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Aug; 44(16):2636-60. PubMed ID: 11472217
[TBL] [Abstract][Full Text] [Related]
44. Expression and purification of correctly processed, active human TACE catalytic domain in Saccharomyces cerevisiae.
Clarke HR; Wolfson MF; Rauch CT; Castner BJ; Huang CP; Gerhart MJ; Johnson RS; Cerretti DP; Paxton RJ; Price VL; Black RA
Protein Expr Purif; 1998 Jun; 13(1):104-10. PubMed ID: 9631522
[TBL] [Abstract][Full Text] [Related]
45. An essential role for ectodomain shedding in mammalian development.
Peschon JJ; Slack JL; Reddy P; Stocking KL; Sunnarborg SW; Lee DC; Russell WE; Castner BJ; Johnson RS; Fitzner JN; Boyce RW; Nelson N; Kozlosky CJ; Wolfson MF; Rauch CT; Cerretti DP; Paxton RJ; March CJ; Black RA
Science; 1998 Nov; 282(5392):1281-4. PubMed ID: 9812885
[TBL] [Abstract][Full Text] [Related]
46. Contribution of TNF-alpha converting enzyme and proteinase-3 to TNF-alpha processing in human alveolar macrophages.
Armstrong L; Godinho SI; Uppington KM; Whittington HA; Millar AB
Am J Respir Cell Mol Biol; 2006 Feb; 34(2):219-25. PubMed ID: 16210695
[TBL] [Abstract][Full Text] [Related]
47. Reverse hydroxamate-based selective TACE inhibitors.
Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
[TBL] [Abstract][Full Text] [Related]
48. TIMP3 checks inflammation.
Black RA
Nat Genet; 2004 Sep; 36(9):934-5. PubMed ID: 15340428
[TBL] [Abstract][Full Text] [Related]
49. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17.
Fabre-Lafay S; Garrido-Urbani S; Reymond N; Gonçalves A; Dubreuil P; Lopez M
J Biol Chem; 2005 May; 280(20):19543-50. PubMed ID: 15784625
[TBL] [Abstract][Full Text] [Related]
50. Biology of TACE inhibition.
Newton RC; Solomon KA; Covington MB; Decicco CP; Haley PJ; Friedman SM; Vaddi K
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii25-32. PubMed ID: 11890648
[TBL] [Abstract][Full Text] [Related]
51. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme.
Maskos K; Fernandez-Catalan C; Huber R; Bourenkov GP; Bartunik H; Ellestad GA; Reddy P; Wolfson MF; Rauch CT; Castner BJ; Davis R; Clarke HR; Petersen M; Fitzner JN; Cerretti DP; March CJ; Paxton RJ; Black RA; Bode W
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3408-12. PubMed ID: 9520379
[TBL] [Abstract][Full Text] [Related]
52. Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme.
Lee MH; Dodds P; Verma V; Maskos K; Knäuper V; Murphy G
Biochem J; 2003 Apr; 371(Pt 2):369-76. PubMed ID: 12556225
[TBL] [Abstract][Full Text] [Related]
53. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor.
Müllberg J; Durie FH; Otten-Evans C; Alderson MR; Rose-John S; Cosman D; Black RA; Mohler KM
J Immunol; 1995 Dec; 155(11):5198-205. PubMed ID: 7594530
[TBL] [Abstract][Full Text] [Related]
54. Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Tsuji F; Oki K; Okahara A; Suhara H; Yamanouchi T; Sasano M; Mita S; Horiuchi M
Cytokine; 2002 Mar; 17(6):294-300. PubMed ID: 12061836
[TBL] [Abstract][Full Text] [Related]
55. Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity.
Black RA; Doedens JR; Mahimkar R; Johnson R; Guo L; Wallace A; Virca D; Eisenman J; Slack J; Castner B; Sunnarborg SW; Lee DC; Cowling R; Jin G; Charrier K; Peschon JJ; Paxton R
Biochem Soc Symp; 2003; (70):39-52. PubMed ID: 14587281
[TBL] [Abstract][Full Text] [Related]
56. Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding.
Thathiah A; Blobel CP; Carson DD
J Biol Chem; 2003 Jan; 278(5):3386-94. PubMed ID: 12441351
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.
Letavic MA; Barberia JT; Carty TJ; Hardink JR; Liras J; Lopresti-Morrow LL; Mitchell PG; Noe MC; Reeves LM; Snow SL; Stam EJ; Sweeney FJ; Vaughn ML; Yu CH
Bioorg Med Chem Lett; 2003 Oct; 13(19):3243-6. PubMed ID: 12951101
[TBL] [Abstract][Full Text] [Related]
58. Shedding of membrane proteins by ADAM family proteases.
Moss ML; Lambert MH
Essays Biochem; 2002; 38():141-53. PubMed ID: 12463167
[TBL] [Abstract][Full Text] [Related]
59. TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha.
Patel IR; Attur MG; Patel RN; Stuchin SA; Abagyan RA; Abramson SB; Amin AR
J Immunol; 1998 May; 160(9):4570-9. PubMed ID: 9574564
[TBL] [Abstract][Full Text] [Related]
60. The shedding activity of ADAM17 is sequestered in lipid rafts.
Tellier E; Canault M; Rebsomen L; Bonardo B; Juhan-Vague I; Nalbone G; Peiretti F
Exp Cell Res; 2006 Dec; 312(20):3969-80. PubMed ID: 17010968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
